Is LABP undervalued or overvalued?
As of 2025-03-17, the Intrinsic Value of Landos Biopharma Inc (LABP) is -39.61 USD. This LABP valuation is based on the model Peter Lynch Fair Value. With the current market price of 22.93 USD, the upside of Landos Biopharma Inc is -272.74%. This means that LABP is overvalued by 272.74%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -39.61 - -39.61 | -39.61 | -272.74% |
| P/E | (127.70) - (156.22) | (136.06) | -693.4% |
| DDM - Stable | (82.09) - (583.64) | (332.86) | -1551.6% |
| DDM - Multi | (66.64) - (382.33) | (114.92) | -601.2% |
| Market Cap (mil) | 71.77 |
| Beta | 0.70 |
| Outstanding shares (mil) | 3.13 |
| Enterprise Value (mil) | 42.77 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.60% |
| Cost of Debt | 5.00% |
| WACC | 6.14% |